These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10436095)

  • 61. Safety and efficacy of MRI-based selection for recombinant tissue plasminogen activator treatment: responder analysis of outcome in the 3-hour time window.
    Sølling C; Hjort N; Ashkanian M; Østergaard L; Andersen G
    Cerebrovasc Dis; 2009; 27(3):223-9. PubMed ID: 19176954
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
    Chapman KM; Woolfenden AR; Graeb D; Johnston DC; Beckman J; Schulzer M; Teal PA
    Stroke; 2000 Dec; 31(12):2920-4. PubMed ID: 11108749
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.
    Smith RW; Scott PA; Grant RJ; Chudnofsky CR; Frederiksen SM
    Acad Emerg Med; 1999 Jun; 6(6):618-25. PubMed ID: 10386679
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cerebral autoregulation dynamics in acute ischemic stroke after rtPA thrombolysis.
    Reinhard M; Wihler C; Roth M; Harloff A; Niesen WD; Timmer J; Weiller C; Hetzel A
    Cerebrovasc Dis; 2008; 26(2):147-55. PubMed ID: 18560218
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke.
    Koga M; Arihiro S; Miyashita F; Yamamoto H; Yamada N; Nagatsuka K; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2013; 36(4):299-305. PubMed ID: 24135558
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.
    Bhatia R; Hill MD; Shobha N; Menon B; Bal S; Kochar P; Watson T; Goyal M; Demchuk AM
    Stroke; 2010 Oct; 41(10):2254-8. PubMed ID: 20829513
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke.
    Firlik AD; Yonas H; Kaufmann AM; Wechsler LR; Jungreis CA; Fukui MB; Williams RL
    J Neurosurg; 1998 Aug; 89(2):243-9. PubMed ID: 9688119
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does clinical-CT 'mismatch' predict early response to treatment with recombinant tissue plasminogen activator?
    Choi JY; Pary JK; Alexandrov AV; Molina CA; Garami Z; Malkoff MD; Rubiera M; Shaltoni HM; Moye LA; Grotta JC
    Cerebrovasc Dis; 2006; 22(5-6):384-8. PubMed ID: 16888380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Decrease in blood pressure after intravenous administration of urapidil during recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke.
    Bugnicourt JM; Duru C; Picard C; Godefroy O
    Clin Ther; 2008 Sep; 30(9):1675-80. PubMed ID: 18840373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review.
    Meseguer E; Mazighi M; Labreuche J; Arnaiz C; Cabrejo L; Slaoui T; Guidoux C; Olivot JM; Abboud H; Lapergue B; Raphaeli G; Klein IF; Lavallée PC; Amarenco P
    Stroke; 2009 Jun; 40(6):2104-10. PubMed ID: 19372440
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
    Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
    Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
    Broderick JP; Lu M; Kothari R; Levine SR; Lyden PD; Haley EC; Brott TG; Grotta J; Tilley BC; Marler JR; Frankel M
    Stroke; 2000 Oct; 31(10):2335-41. PubMed ID: 11022060
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Relation between reperfusion and hemorrhagic transformation in acute ischemic stroke.
    Horsch AD; Dankbaar JW; van der Graaf Y; Niesten JM; van Seeters T; van der Schaaf IC; Kappelle LJ; Velthuis BK;
    Neuroradiology; 2015 Dec; 57(12):1219-25. PubMed ID: 26337766
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.
    Vandelli L; Marietta M; Trenti T; Varani M; Bigliardi G; Rosafio F; Dell'acqua ML; Picchetto L; Nichelli P; Zini A
    Adv Clin Exp Med; 2019 Feb; 28(2):219-222. PubMed ID: 30507073
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke.
    Saur D; Kucinski T; Grzyska U; Eckert B; Eggers C; Niesen W; Schoder V; Zeumer H; Weiller C; Röther J
    AJNR Am J Neuroradiol; 2003 May; 24(5):878-85. PubMed ID: 12748088
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CT interpretation in a telestroke network: agreement among a spoke radiologist, hub vascular neurologist, and hub neuroradiologist.
    Demaerschalk BM; Bobrow BJ; Raman R; Ernstrom K; Hoxworth JM; Patel AC; Kiernan TE; Aguilar MI; Ingall TJ; Dodick DW; Meyer BC;
    Stroke; 2012 Nov; 43(11):3095-7. PubMed ID: 22984007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.